A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity Against HER2-Positive Breast Cancer In Vitro and In Vivo

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Mar 28

PMID 38542884

Authors

Junmin Li

Yanting Zhou

Zhuowei Su

Xue Li

Lei Zhang

Shan Li

Affiliations

Soon will be listed here.

Abstract

Cell-penetrating peptides (CPPs) are invaluable tools for delivering various substances into cells by crossing biological membranes. However, the effects of cell-penetrating peptide fusion proteins on the biological activity of antibodies remain to be fully understood. Here, we engineered a recombinant protein, LP-scFv, which combines the single-chain variable region of anti-human epidermal growth factor receptor-2 with a novel and non-oxic cell-penetrating peptide as a leader peptide. The introduction of this leader peptide led to a more than twofold increase in the internalization efficiency of the single-chain antibody, as confirmed using microscopic analysis and flow cytometry. The effects of the single-chain antibodies and LP-scFv on cell viability were evaluated using the MTT assay. Both the single-chain antibodies and LP-scFv reduced the viability of BT474 and NCI-N87 cells in a dose-dependent manner while exhibiting minimal toxicity towards MCF-7 and MCF-10A cells. Further investigation into LP-scFv's mechanism revealed that the induced leader peptide does not alter the MAPK-ERK1/2 and PI3K/AKT pathways of single-chain antibodies. An enhanced antitumor activity was also confirmed in an NCI-N87 tumor xenograft model in mice with a reduction of 45.2% in tumor growth inhibition (vs. 23.1% for scFv) with a 50 mg/kg dose after orthotopic injection administration, which was equivalent to that of trastuzumab (vs. 55.7% for trastuzumab). Overall, these results indicate that LP-scFv exhibits significant permeation activity in HER2-positive cells to enhance the intracellular dose effect on antitumor activity in vitro and in vivo. This research lays the foundation for designing novel antibody-based therapies for cancer.

References

Bennion B, Be N, McNerney M, Lao V, Carlson E, Valdez C . Predicting a Drug's Membrane Permeability: A Computational Model Validated With in Vitro Permeability Assay Data. J Phys Chem B. 2017; 121(20):5228-5237. DOI: 10.1021/acs.jpcb.7b02914. View

Busch J, Fielden L, Pfanner N, Wiedemann N . Mitochondrial protein transport: Versatility of translocases and mechanisms. Mol Cell. 2023; 83(6):890-910. DOI: 10.1016/j.molcel.2023.02.020. View

Hamilton E, Shastry M, Shiller S, Ren R . Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021; 100:102286. DOI: 10.1016/j.ctrv.2021.102286. View

Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky B, Wine Y . The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Front Immunol. 2020; 11:1951. PMC: 7461797. DOI: 10.3389/fimmu.2020.01951. View

Deonarain M, Xue Q . Tackling solid tumour therapy with small-format drug conjugates. Antib Ther. 2021; 3(4):237-245. PMC: 7990258. DOI: 10.1093/abt/tbaa024. View

Wang Y, Lee H, Lee H, Du Y, Yamaguchi H, Hung M . Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. J Biol Chem. 2012; 287(20):16869-79. PMC: 3351284. DOI: 10.1074/jbc.M111.314799. View

Austin C, De Maziere A, Pisacane P, van Dijk S, Eigenbrot C, Sliwkowski M . Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004; 15(12):5268-82. PMC: 532009. DOI: 10.1091/mbc.e04-07-0591. View

Li Z, Zhang Q, Wang H, Zhang Y, Ding D, Pan L . Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin. Invest New Drugs. 2013; 32(1):75-86. DOI: 10.1007/s10637-013-9995-y. View

Darzynkiewicz Z, Galkowski D, Zhao H . Analysis of apoptosis by cytometry using TUNEL assay. Methods. 2008; 44(3):250-4. PMC: 2295206. DOI: 10.1016/j.ymeth.2007.11.008. View

10.

Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Lleres D . The cell proliferation antigen Ki-67 organises heterochromatin. Elife. 2016; 5:e13722. PMC: 4841783. DOI: 10.7554/eLife.13722. View

11.

Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y . Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2006; 59(6):795-805. DOI: 10.1007/s00280-006-0337-z. View

12.

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C . Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021; 17(33):4635-4647. DOI: 10.2217/fon-2021-0742. View

13.

Sauter M, Strieker M, Kleist C, Wischnjow A, Daniel V, Altmann A . Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. J Control Release. 2020; 322:200-208. DOI: 10.1016/j.jconrel.2020.03.005. View

14.

Del Genio V, Falanga A, Allard-Vannier E, Herve-Aubert K, Leone M, Bellavita R . Design and Validation of Nanofibers Made of Self-Assembled Peptides to Become Multifunctional Stimuli-Sensitive Nanovectors of Anticancer Drug Doxorubicin. Pharmaceutics. 2022; 14(8). PMC: 9331957. DOI: 10.3390/pharmaceutics14081544. View

15.

Xu K, Lee F, Gao S, Tan M, Kurisawa M . Hyaluronidase-incorporated hyaluronic acid-tyramine hydrogels for the sustained release of trastuzumab. J Control Release. 2015; 216:47-55. DOI: 10.1016/j.jconrel.2015.08.015. View

16.

Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Lacasse V, Beaudoin S, Jean S, Leyton J . A Novel Proteomic Method Reveals NLS Tagging of T-DM1 Contravenes Classical Nuclear Transport in a Model of HER2-Positive Breast Cancer. Mol Ther Methods Clin Dev. 2020; 19:99-119. PMC: 7522293. DOI: 10.1016/j.omtm.2020.08.016. View

19.

Bae J, Song Y . Engineering a cell-penetrating hyperstable antibody scFv(Ras) - An extraordinary approach to cancer therapeutics. Synth Syst Biotechnol. 2021; 6(4):343-350. PMC: 8531465. DOI: 10.1016/j.synbio.2021.10.002. View

20.

Chacinska A, Koehler C, Milenkovic D, Lithgow T, Pfanner N . Importing mitochondrial proteins: machineries and mechanisms. Cell. 2009; 138(4):628-44. PMC: 4099469. DOI: 10.1016/j.cell.2009.08.005. View